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Background: The surgical treatment of patients with invasive lobular carcinoma is still controversial due
to its different clinical and pathological features. Most studies report local recurrence after relatively
short follow-up periods, which is usually 5 years. However there is some evidence to suggest that local
recurrence may occur late in the course of follow-up.
Aim of the study: To study the implications and outcome of extending the follow-up period of patients
treated for invasive lobular carcinoma.
Patients and methods: Patients (268) treated between 1989 and 1996 were reviewed. Thirty-three
patients were excluded as they had primary hormonal therapy. The outcomes for 235 patients were
analyzed.
Results: Seventy-nine patients (33.6%) had breast conservation surgery (group I), which was followed by
re-excision due to positive margins in 23 patients (29%), and 156 patients (66.3%) had mastectomy (group
II). Compared to group II, tumours in group I were smaller (mean size17 vs. 37 mm, P¼ 0.001), multifocal
[20 (25%) vs. 14 (9%), P¼ 0.003] and with more positive margins [23 (29%) vs. 24 (15%), P¼ 0.0009]. Only
33 patients (21%) in group II, and all patients in group I had post-operative radiotherapy (P¼ 0.0001).
Forty-eight patients (17.9%) developed local recurrence [27 (34%) in group I and 21 (13.4%) in group II,
P¼ 0.0005] after a median follow-up period of 167.8 months. The mean time to local recurrence was 127
(range 24e196) months. Univariate analysis showed that the type of surgery, margin status, adjuvant
radiotherapy and chemotherapy signiﬁcantly affected local recurrence (P¼ 0.0005, 0.02, 0.04 and 0.05
respectively). Cox regression analysis showed that the only factor affected local recurrence was the type
of surgery (relative risk 2.43, 95% conﬁdence interval 1.22e4.83, P¼ 0.01)
The overall survival was 99.3 months (78.2%). Univariate and Cox regression analyses showed that
only the patients age at diagnosis signiﬁcantly affected survival (P¼ 0.003).
Conclusion: Local recurrence may be a late event in patients treated for invasive lobular carcinoma of the
breast and extended follow-up may be considered. In this study mastectomy offers better local control.
 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Invasive lobular carcinoma accounts for 5e15% of breast
cancers.1,2 There is an increasing interest in understanding invasive
lobular carcinoma as data from some epidemiological studies
indicate that the incidence of this type of breast cancer is
increasing3 disproportionate to the incidence of invasive ductal
carcinoma.4 The exact cause for this discrepancy is not known, but
the increasing use of hormone replacement therapy could be7.
ssien).
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ciates Ltd. Published by Elsevier Lta factor in view of the higher proportions of estrogen receptor
positive lobular carcinoma than ductal carcinoma.4 On the contrary,
a recent study reported that the incidence of invasive lobular
carcinoma has decreased in the United States between 1999 and
2004.5 It is not clear whether ductal carcinoma and lobular carci-
noma represent molecularly distinct entities and what genes might
be involved in the development of these two phenotypes.6,7
Lobular carcinoma often fail to form distinct masses that can be
easily diagnosed by palpation, and this can make the clinical diag-
nosis challenging.8,9 It has decreased association with micro-
calciﬁcation which results in a lower detection rate on screening
than invasive ductal carcinoma.3 Therefore, mammographic diag-
nosis of invasive lobular carcinoma is difﬁcult and sometimes
misleading, with a reported false negative rate of 19%.8 Bothd. All rights reserved.
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tumour in up to 53%.10e12 The biological characteristics of invasive
lobular carcinoma makes it difﬁcult to estimate the extent of the
disease and also to detect axillary lymph node metastasis.13 It
appears to have a substantially increased propensity for multifocal
andmulticentricdistribution.14e16 Therefore, preoperativemagnetic
resonance imaging has been advocated to detect multiple lesions.12
The surgical management of invasive lobular carcinoma is still
controversial. The incidence of re-excision due to positive margins
and completion mastectomy in invasive lobular carcinoma are
signiﬁcantly higher than in invasive ductal carcinoma.11,17 This
ﬁnding has led some surgeons to believe that more aggressive
therapy is needed. At present, management decisions are based on
individual patients and tumour biological pattern and not on
lobular histology.3
Invasive lobular carcinoma is more often hormone receptor
positive compared to invasive ductal carcinoma, which may be the
reason for improvement of the overall survival reported in some
studies.18 It is often low or intermediate grade and has a low
proliferative index.19 It has a lower response to chemotherapy than
invasive ductal carcinoma because of its immunohistochemical
proﬁle.20,21 Therefore, the use of neo-adjuvant chemotherapy in
cases of invasive lobular carcinoma may be questioned.21
Because it is substantially less common than invasive ductal
carcinoma, knowledge about the clinical outcome of invasive
lobular carcinoma has been based on studies including relatively
small number of patients, which reported different ranges of
prognosis either worse,22 similar23 or better19 than invasive ductal
carcinoma. A recent published study has suggested that invasive
lobular carcinoma is more than a histologic variant of breast cancer
because it has prognostic and biologic implications which are
apparent after extended follow-up period.24
This work was conducted to study the clinical outcome of
invasive lobular breast carcinoma in terms of adequacy of surgical
management and local recurrence rate with longer periods of
follow-up.
2. Patients and methods
2.1. Inclusion and exclusion criteria
All patients diagnosed with invasive lobular carcinoma of the
breast treated at Norfolk & Norwich University Hospital between
December 1989 and December 1996 were studied retrospectively.
Data were obtained from the Regional Cancer Registry, Cambridge.
Patients with mixed ductal and lobular tumours, and patients who
were treated conservatively with hormonal therapy were excluded.
Data recorded included patient age, type of surgery performed and
the details of the tumour pathology. This includes the tumour size,
grade, presence of DCIS and LCIS, margins, lymphovascular inva-
sion, multifocality and lymph node metastasis. Tumour grade was
determined by using the Nottingham combined histological
grading system, which assesses the degree of nuclear pleomor-
phism and the mitotic count. Adjuvant therapy was recorded. Local
recurrence and distant metastasis events as well as survival were
recorded.
2.2. Type of surgery
Indications for mastectomy were large tumour/breast ratio,
multicentric disease, central tumours or patient’s choice. Other
patients were offered breast conservation. All patients had axillary
clearance regardless of the type of primary surgery in accordance
with the Unit’s protocol during the study period. Positive margins
were deﬁned as invasive disease or DCIS at the margins. Patientswith positive margins after breast conservation surgery had further
re-excision to obtain clear margins. During the study period,
quadrantectomy was considered adequate surgery for multifocal
disease provided that the margins were clear.
Patients were divided into two groups according to the type of
surgical treatment. Group I breast conserving surgery, and group II
were patients who had mastectomy. The two groups were
compared.
2.3. Adjuvant treatment
All patients treated with breast conservation surgery received
adjuvant radiotherapy according to the Unit’s protocol during the
study period (4000 Gy over 4 weeks). Indications for post-
mastectomy radiotherapy were large tumours (T4), 3 or more
positive lymph glands and positive margins. Patients with estrogen
receptor positive breast carcinoma received tamoxifen treatment
for 5 years. High risk patients had chemotherapy according to the
Unit’s protocol. Patients were followed-up annually. Multifocality
was deﬁned as multiple foci of histologically conﬁrmed invasive
carcinoma in the same quadrant of the breast. Multicentricity was
deﬁned as multiple foci of histologically conﬁrmed invasive carci-
noma in different quadrants of the breast. Local recurrence was
deﬁned as invasive carcinoma in the treated breast or the mastec-
tomy site.
2.4. Statistical analysis
Statistical analysis was performed at the department of medical
statistics at the University of East Anglia. Chi-square and t-test were
performed for the univariate analysis of variables listed in Table 1.
Patterns of variation in elapsed times (months) between surgery
and local recurrence or death were investigated via Cox Regression
(Cox’s Proportional Hazards Model). A pool of variables listed in
Table 1 was submitted to a forward stepwise search procedure to
identify a parsimonious model, containing only effects that were
jointly statistically signiﬁcant while excluding effects that were not
statistically signiﬁcant. Values are presented with their exact values
or rounded to two digits and considered signiﬁcant if 0.05.
3. Results
Patients (268) diagnosed with invasive lobular carcinoma were
identiﬁed. This accounts for 5% of invasive breast carcinoma treated
in the unit during the period of the study (5259 patients). 33
patients were excluded from the study, as they had primary
hormonal treatment. 235 patients were included in the analysis.
Patients mean age was 60.6 (range 27e88) years. 79 Patients
who had breast conservation surgery (Group I) were compared to
156 patients who had mastectomy (Group II). Table 1 shows the
details of variables in the two groups. Multifocality was detected in
20 patients (25%) in group I vs. 14 patients (9%) in group II
(P¼ 0.003). Margins were positive in 23 patients (29%) in group I vs.
24 (15%) patients in group II (P¼ 0.0009). All patients with positive
margins in group I had re-excision to obtain clear margins. The
median follow-up period was 167.8 months.
Local recurrence occurred in 48 patients (17.9%), 27 patients
(34%) in group I and 21 patients (13.4%) in group II. Univariant
analysis showed factors which signiﬁcantly affected local recur-
rence were type of primary surgery, margins and adjuvant treat-
ment (Table 2). The overall mean time to local recurrence was 127
(range 24e196) months. The mean time to local recurrence in
group I patients was 112 vs. 133.5 months in group II patients
(P¼ 0.04). Cox Regression analysis showed that the only signiﬁcant
variable that affected local recurrence was the type of surgery (risk
Table 1
Variables in both groups.
Variable Group I breast
conservation 79
patients
Group II
mastectomy 156
patients
Total P
Age at diagnosis (years)
< 50 19 (24%) 29 (18.5%) 48 0.38
50e59 20 (25%) 47 (30%) 67
60e69 22 (27.8%) 51 (32.6%) 73
70þ 18 (22.7%) 29 (18.5%) 47
Tumor size (mm)
<20 45 (57%) 42 (27%) 87 0.008*
21-50 34 (43%) 58 (37%) 92
> 50 - 56 (36%) 56
Tumor grade
Low/
intermediate
59 (74.6%) 126 (80.7%) 185 0.51
High 14 (17.7%) 20 (12.8%) 34
Not deﬁned 6 (7.5%) 10 (6.4%) 16
Growth pattern
Unicentric 56 (71%) 138 (88%) 194 0.003*
Multifocal 20 (25%) 14 (9%) 34
Multicentric 3 (4%) 4 (3%) 7
Lymph nodes
Positive (1e3
nodes)
18 (24.7%) 26 (16.6%) 44 0.56
Positive (<3
nodes)
1 (1.2%) 5 (3.2%) 6
Negative 60 (76%) 125 (80%) 185
Type of surgery
Quadrantectomy 79 - 235
Mastectomy - 156
Margins
Positive 23 (29%) 24 (15%) 47 0.0009*
Negative 56 (71%) 132 (85%) 188
Estrogen Receptors (ER)
Positive 66 (83.5%) 134 (85.8%) 200 0.63
Negative 13 (16.4%) 22 (14.1%) 35
LCIS
Present 34 (43%) 50 (32%) 84 0.12
Absent 45 (57%) 106 (68%) 151
LVI
Present 17 (21.5%) 31 (20%) 48 0.9
Absent 62 (78.4%) 125 (80%) 187
Adj. Radiotherapy
Yes 79 (100%) 33 (21%) 112 <0.001*
No 0 123 (79%) 123
Adj. Chemotherapy
Yes 9 (11%) 23 (15%) 32 0.61
No 70 (89%) 133 (85%) 203
Values expressed by numbers of patients (% within the group).
LCIS: lobular carcinoma in situ, Adj: adjuvant, LVI: lymphovascular invasion, posi-
tive margin: invasive or in-situ ductal malignancy at the margin, *: signiﬁcant.
Table 2
Analysis of local recurrence (numbers shown are patient’s numbers).
Variable No. of patient Local recurrence P
Age at diagnosis (years)
<50 48 7 0.68
50e59 67 19
60e69 73 11
70þ 47 11
Tumour size(mm)
<20 87 14 0.34
21e50 92 22
>50 56 12
Tumour grade
Low/intermediate 185 35 0.32
High 34 10
Not deﬁned 16 3
Growth pattern
Unicentric 194 37 0.28
Multifocal 34 8
Multicentric 7 3
Estrogen receptors (ER)
Positive 200 38 0.27
Negative 35 10
Lymph nodes
Positive (1e3 nodes) 44 12 0.27
Positive (<3 nodes) 6 1
Negative 185 35
Type of surgery
Quadrantectomy 79 27 0.0005*
Mastectomy 156 21
Margins
Positive 47 15 0.02*
Negative 188 33
LCIS
Present 84 18 0.37
Absent 151 24
LVI
Present 48 35 0.27
Absent 187 13
Adj. Radiotherapy
Yes 112 29 0.04*
No 123 19
Adj. Chemotherapy
Yes 32 10 0.05*
No 203 38
*: Signiﬁcant, LCIS: lobular carcinoma in situ, Adj: adjuvant, LVI: lymphovascular
invasion, positive margin: invasive or in-situ ductal malignancy at the margin.
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no evidence of signiﬁcant interaction between type of surgery and
other variables, and its effects is considered to be independent of
other variables studied.
The survival analysis included breast cancer as well as other
causes of mortality (all-cause mortalities). The overall survival was
99.3 months (78.2%). There was no signiﬁcant difference in the
overall survival between group I and group II patients (94.9 vs.101.3
months respectively, P¼ 0.47). Local recurrence did not affect the
overall survival (P¼ 0.1). Univariate analysis of variables showed
that the age at diagnosis was found to have a statistically signiﬁcant
impact on the overall survival (P¼ 0.003) (Table 3). Cox Regression
analysis showed that age at diagnosis signiﬁcantly affected survival.Relative to patients aged 70 years and over when diagnosed;
patients aged under 50 years at diagnosis had a risk of death of 0.6
(95% conﬁdence interval 0.26e1.38, P¼ 0.23); patients aged 50e59
years at diagnosis had a risk of death of 0.1 (95% conﬁdence interval
0.02e0.3, P¼ 0.001); and patients aged 60e69 years at diagnosis
had a risk of death of 0.5 (95% conﬁdence interval 0.23e0.95,
P¼ 0.03). This ﬁnding reﬂects the expected increasedmortality rate
with increasing age. Figs. 1 and 2 show Kaplan Meier curve of local
recurrence and survival of patients in both groups.
Distant metastasis occurred only in 9 patients (3.8%). Multi-
variant analysis showed no signiﬁcant association between
different variables and distant metastasis.
4. Discussion
4.1. Age
It has been reported that invasive lobular carcinoma occurs
more among older women than duct carcinoma, with the median
Table 3
Analysis of survival (numbers shown are patient’s numbers).
Variable No. of
patients
Survival P
Alive (184
patients)
Dead (51
patients)
Age at diagnosis (years)
<50 48 47 1 0.03*
50-59 67 54 13
60-69 73 57 16
70þ 47 26 21
Tumour size(mm)
<20 87 76 11 0.96
21e50 92 67 25
>50 56 41 15
Tumour grade
Low/intermediate 185 144 41 0.3
High 34 26 8
Not deﬁned 16 14 2
Growth pattern
Unicentric 194 154 40 0.7
Multifocal 34 25 9
Multicentric 7 5 2
Lymph nodes
Positive (1e3
nodes)
44 34 10 0.06
Positive (<3 nodes) 6 2 4
Negative 185 148 37
Type of surgery
Breast
Conservation
79 67 12 0.51
Mastectomy 156 117 39
Estrogen receptors (ER)
Positive 200 157 43 0.85
Negative 35 27 8
Margins
Positive 47 37 10 0.91
Negative 188 147 41
LCIS
Present 84 71 13 0.46
Absent 151 113 38
LVI
Present 48 39 9 0.17
Absent 187 145 42
Adj. Radiotherapy
Yes 112 87 25 0.27
No 123 97 26
Adj. Chemotherapy
Yes 32 26 6 0.9
No 203 158 45
Survival includes All-cause mortalities.
*: Signiﬁcant, LCIS: lobular carcinoma in situ, Adj.: adjuvant; LVI: lymphovascular
invasion, positive margin: invasive or in-situ ductal malignancy at the margin.
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not reproduce this ﬁnding and reported similar age of patients with
invasive carcinoma at diagnosis.9,28 In the current study themedian
age was 60.6 years, but we did not compare this with ducal carci-
noma patients.
The relation of age to overall survival and local recurrence has
also been studied and some reports suggested that age<50 years is
a poor prognostic factor as it is associated with greater risk of local
recurrence.29,30 Schnitt and colleagues 1989, who reviewed 49
patients with invasive lobular carcinoma, found that patients aged
45 years or younger had a signiﬁcantly higher risk of local recur-
rence (40% vs. 8%) after 5 years of follow-up.31 In the present study,
age at the diagnosis did not have any inﬂuence on local recurrence.On the other hand we found increased mortality rate with
increasing age, as mortality in this study represents all-cause
mortalities (Table 3).
4.2. Tumour size
Invasive lobular carcinoma is frequently reported to be larger
than invasive duct carcinoma, due to the delay in diagnosis and lack
of discrete mass formation. Yeatman analyzed the tumour biology
of 74 patients with invasive lobular carcinoma in comparison to 661
patients with invasive duct carcinoma, and reported that the
lobular carcinoma was signiﬁcantly larger at diagnosis (3.2 cm vs.
2.2 cm).9 In another study that analyzed 726 invasive lobular
carcinomas, 19% of the lobular carcinoma were larger than 5 cm
compared to 12% of non-lobular carcinoma.32 In the present study
the mean tumour size was 23.3 mm and 24% of tumours were
larger than 50 mm at diagnosis. Tumour size had no signiﬁcant
inﬂuence on survival or local recurrence and this agrees with
previous reports.17
4.3. Type of primary surgery
Numerous prospective randomized trials conﬁrm equivalent
survival and local recurrence rates for both mastectomy and breast
conservation surgery (partialmastectomyandadjuvant radiotherapy)
Table 4
Studies with long follow-up periods.
Author/year No of patients Median follow-
up (months)
Local
recurrence %
Type of surgery
Lobular Ductal
Kurtz,
198939
67 709 71 13% Lobular BCS *
9% Ductal
Mate,
198629
12 168 83 25% Lobular BCS *
13% Ductal
Du Toit,
199128
171 324 64 BCS BCS
*Mastectomy
(NS)
42%
Lobular
17%
Ductal
Mastectomy
27%
Lobular
21
Ductal
Warneke,
199642
111 84 BCS 3% Lobular BCS v
Mastectomy
(NS)
71 Mastectomy NS
Hussien,
200317
131 90 42% BCS BCS v
Mastectomy *5%
Mastectomy
Saster-
Garau,
199625
480 1061 82 NS BCS (NS)
Silverstein,
199432
161 1138 78 5% overall BCS and
Mastectomy
(NS)
Schnitt,
198931
49 561 75 12% Lobular BCS (NS)
5% Ductal
BCS: breast conservation Surgery, NS: not signiﬁcant, *: signiﬁcant.
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Multiple investigations have focused on identifying factors that may
affect local recurrence after breast conservation surgery such as
margins, presence of in-situ carcinoma or lymphovascular invasion,
tumour size and grade and adjuvant treatment.36,37
Some reports have expressed reservation in treating invasive
lobular carcinoma with breast conservation because of multi-
focality, multicentricity and it’s propensity to inﬁltrate the
surrounding breast tissue.7,38 This causes a high percentage of
positive margins after breast conservation and leads to subse-
quent re-excision or completion mastectomy to achieve local
control. In our study, 20 patients (25%) in group I versus 14
patients (9%) in group II were found to have multifocal tumours.
According to the Unit’s protocol during the study period, quad-
rantectomy followed by radiotherapy was considered adequate
local therapy for multifocal disease. Multifocality was conﬁrmed
only after quadrantectomy in some patients but no further
treatment recommended afterwards. This is one of the major
weaknesses of our study, and could explain the high rate of local
recurrence in group I patients. Multifocality did not signiﬁcantly
affect local recurrence (P¼ 0.28, Table 2), but this could be due to
the small numbers of patients in this study. In most recent breast
surgery units, accurate preoperative assessment of breast tumours
can be achieved by modern digital mammography, ultrasonog-
raphy and magnetic resonance (MRI) scan. According to the
recent guidelines, we now recommend mastectomy for patients
with proven multifocal disease whether diagnosed pre or post-
operatively even if the margins (after breast conservation) are
clear.
As with invasive ductal carcinoma of the breast, the treatment of
invasive lobular carcinoma has evolved away frommastectomy and
towards breast conservation procedures as the type of surgery does
not affect survival.26,32 Few studies have compared mastectomy
and breast conservation surgery in lobular carcinoma patients.17
Some authors have suggested that mastectomy is the treatment
of choice of invasive lobular carcinoma to reduce the high rate of
local recurrence.17 Other authors observed that the number of
patients who required completion mastectomy after breast
conservation was several-fold, higher with invasive lobular
compared to invasive duct carcinoma.9 Several reports have shown
a higher rate of local recurrence in patients with invasive lobular
carcinoma treated by breast conservation compared to patients
with invasive duct carcinoma (Table 4).29,39
4.4. Follow-up period and local recurrence
In our study 48 patients were diagnosed with local recurrence
(17.9%). A signiﬁcantly higher proportion of local recurrence
occurred in the breast conservation surgery group compared to
patients who had mastectomy (34% vs. 13.4%, P¼ 0.0005), and this
would agree with pervious reports.17,28,39,40 We believe that one of
the most important ﬁndings of our study is adding a further
evidence to support that local recurrence in patients treated for
invasive lobular carcinoma may be a delayed event. The mean time
to local recurrence was 127 (range 24e196) months irrespective of
the type of primary surgery. The mean time to local recurrence in
patients who had breast conservation surgery (group I) was
signiﬁcantly shorter than in patients who had mastectomy (group
II). In both groups the local recurrence may be a late event. We
could not observe a similar pattern in survival analysis.
Some studies which extended the period of follow-up beyond
the currently recommended 5 years period showed a higher rate of
local recurrence following breast conservation of lobular carcinoma
compared to ductal carcinoma (Table 4).28,29,39 Kurtz and
colleagues 1989, compared 67 patients who were treated by breastconservation for invasive lobular carcinoma to 709 patients who
had the same treatment for invasive ductal carcinoma after a mean
follow-up period of 5.9 years.39 Mate and colleagues 1986,
compared 12 invasive lobular to 168 patients with invasive ductal
carcinoma.29 These two studies extended the follow-up period
beyond 5 years and both had reported a higher rate of local
recurrence with lobular carcinoma compared to ductal carcinoma.
Du Toit and his colleagues 1991, also extended the follow-up period
to 64 months and reported a local recurrence rate of 42% after
breast conservation for invasive lobular carcinoma, compared to
17% for invasive duct carcinoma, while the local recurrence rate
after mastectomy was not signiﬁcant between the two groups.28
Holland 1995, reviewed 226 invasive lobular carcinoma patients
and reported no signiﬁcant difference in local recurrence after
breast conservation or mastectomy after 55 months of follow-up.41
However, local recurrence in invasive lobular carcinoma patients
can be a late event.17 Warneke 1996, who reviewed 111 patients,
compared invasive lobular carcinoma with mixed invasive lobular
and ductal carcinoma.42 They reported that the difference in local
recurrence rates was not signiﬁcant comparing breast conservation
surgery to mastectomy after a median follow-up period of 83.6
months for breast conservation and 71 months for mastectomy.42
However, this study could have been biased by including the
mixed type of carcinoma as well as the different follow-up periods
between the two groups compared.42
The most recent report on invasive lobular carcinoma was
reported by Pestalozzi and colleagues 2008.24 They compared 767
patients with invasive lobular carcinoma to 8607 patients with
invasive ductal carcinoma treated in different clinical trials
between 1978 and 2002.24 They found that invasive lobular carci-
noma patients were older, had larger but better differentiated
estrogen receptor positive tumours, which required mastectomy
more often than invasive ductal carcinoma patients.24 The most
important ﬁnding in their study was that the disease free and
overall survival has changed when the follow-up period was
extended. Although the disease free and overall survival were
better for invasive lobular carcinoma than ductal carcinoma in the
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the latter years of follow-up. There was no signiﬁcant difference in
local recurrence rates between lobular and ducal carcinomas.
However, the authors did not study the difference in local recur-
rence rates between patients who had mastectomy and those who
had breast conservation for invasive lobular carcinoma. Other
criticisms to this study include different treatment protocols in the
large number of trials studied over a long period of time.24 In our
study, by observing the local recurrence curve (Fig. 1), it is clear that
patients who had breast conservation surgery had more frequent
local failure than those who had mastectomy when the follow-up
was extended longer than 5 years. We did not compare lobular and
ductal carcinomas.
The change of outcome with extending the follow-up period
was previously reported when estrogen receptor positive and
negative breast carcinoma were compared.43,44 Local recurrence
rate in estrogen receptor positive is less than in estrogen receptor
negative breast carcinoma during the initial years of follow-up, but
the local recurrence rate in later years of follow-up was
reversed.43,44 Invasive lobular carcinoma is more likely to be an
estrogen receptor positive, and a similar pattern could be expected.
5. Recommendations and conclusion
It is important to deﬁne speciﬁc management strategies for
patients with invasive lobular carcinoma. We recommend and
encourage colleagues in specialized breast units to study and report
their results after prolonged follow-up periods. Recent evidence
suggests that survival outcome could be different if it is studied
with a longer periods of follow-up.24 Our study provides a similar
observation with local recurrence by comparing breast conserva-
tion surgery and mastectomy. This may indicate that invasive
lobular carcinoma could be considered as a chronic disease irre-
spective of the type of primary surgery. It may also suggest that
extended endocrine treatment could be one of the future paths in
the management of those patients.
In conclusion, local recurrence may be a late event in patients
who had surgery for invasive lobular carcinoma and extended
follow-up may be considered. In this study mastectomy offers
better local control than breast conservation surgery.
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